Apellis Pharmaceuticals Inc
F:1JK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Apellis Pharmaceuticals Inc
F:1JK
|
US |
|
Celestial Asia Securities Holdings Ltd
F:CE0
|
HK |
|
Soitec SA
F:SOH1
|
FR |
|
01 Communique Laboratory Inc
XTSX:ONE
|
CA |
|
Banco Santander SA
OTC:BCDRF
|
ES |
|
C
|
China Oilfield Services Ltd
F:CO9
|
CN |
Wall St Price Targets
1JK Price Targets Summary
Apellis Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for 1JK is 23.08 EUR with a low forecast of 12.43 EUR and a high forecast of 27.69 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 1JK's stock price target?
Price Target
23.08
EUR
According to Wall Street analysts, the average 1-year price target for 1JK is 23.08 EUR with a low forecast of 12.43 EUR and a high forecast of 27.69 EUR.
What is the Revenue forecast for Apellis Pharmaceuticals Inc?
Projected CAGR
9%
The compound annual growth rate for Revenue over the next 8 years is 9%.
What is the Operating Income forecast for Apellis Pharmaceuticals Inc?
Projected CAGR
38%
The compound annual growth rate for Operating Income over the next 8 years is 38%.
What is the Net Income forecast for Apellis Pharmaceuticals Inc?
Projected CAGR
49%
The compound annual growth rate for Net Income over the next 8 years is 49%.
